logo
Plus   Neg
Share
Email

Vivet : FDA Authorizes To Proceed With Phase 1/2 Study On Gene Therapy For Wilson Disease

Vivet Therapeutics, a privately held gene therapy biotech company, and Pfizer Inc. (PFE) said Wednesday that the U.S. Food and Drug Administration has cleared Vivet's Investigational New Drug or IND application for the GATEWAY study for the potential treatment of Wilson disease, a rare and potentially life-threatening liver disorder.

The study is a phase 1/2 clinical trial that will evaluate Vivet's proprietary, investigational gene therapy vector, VTX-801. Vivet expects to enroll the first patient in early 2021.

VTX-801 is a novel, investigational rAAV-based gene therapy vector designed to deliver a miniaturized ATP7B transgene encoding, a functional protein that has been shown to restore copper homeostasis, reverse liver pathology and reduce copper accumulation in the brain of a mouse model of Wilson disease.

The GATEWAY trial will measure relevant biomarkers to evaluate physiological restoration of copper elimination and transport in patients.

In March 2019, Pfizer acquired a minority equity interest in Vivet and secured an exclusive option to acquire all outstanding shares.

In September 2020, Vivet and Pfizer signed an agreement for the manufacture by Pfizer of the VTX-801 vector for the GATEWAY study.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
General Electric Co. filed a lawsuit against Siemens Energy AG, accusing the German power distribution company of stealing trade secrets for gas turbines. Siemens Energy allegedly used the information to get at least nine contracts to supply gas turbines to public utilities, and also covered up improper business gains. Following a court ruling, the U.S. Food and Drug Administration postponed the effective date for tobacco manufacturing companies to display new health warnings on cigarette packets and in advertisements, by additional 90 days. The warnings with color images is to promote greater public understanding of the negative health consequences of smoking. JPMorgan Chase & Co (JPM) reported strong results in the fourth quarter of 2020, with net profit up 42% largely driven by credit reserve releases of $2.9 billion. The Group said it ended the year with a CET1 ratio of 13.1% and capital above $200 billion, providing with meaningful capacity to further...
Follow RTT